Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 367,632
  • Shares Outstanding, K 155,119
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,700 K
  • EBIT $ -111 M
  • EBITDA $ -104 M
  • 60-Month Beta 2.00
  • Price/Sales 579.69
  • Price/Cash Flow N/A
  • Price/Book 10.37

Options Overview Details

View History
  • Implied Volatility 88.76% ( -19.35%)
  • Historical Volatility 109.92%
  • IV Percentile 8%
  • IV Rank 7.55%
  • IV High 273.17% on 12/09/24
  • IV Low 73.71% on 02/20/25
  • Put/Call Vol Ratio 0.08
  • Today's Volume 1,504
  • Volume Avg (30-Day) 2,031
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 86,881
  • Open Int (30-Day) 82,225

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.15
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +20.50%
on 05/20/25
2.93 -17.75%
on 06/06/25
+0.17 (+7.59%)
since 05/16/25
3-Month
1.15 +109.57%
on 04/08/25
3.36 -28.27%
on 03/24/25
-0.63 (-20.72%)
since 03/14/25
52-Week
1.15 +109.57%
on 04/08/25
9.79 -75.38%
on 07/31/24
-4.64 (-65.82%)
since 06/14/24

Most Recent Stories

More News
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

HUMA : 2.41 (+1.69%)
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

HUMA : 2.41 (+1.69%)
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

HUMA : 2.41 (+1.69%)
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

HUMA : 2.41 (+1.69%)
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

HUMA : 2.41 (+1.69%)
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish

Fourth-quarter loss per share came in at $0.16, lower than the $0.24 in the corresponding period of 2023, and below the consensus estimate of $0.25, according to FinChat data.

HUMA : 2.41 (+1.69%)
VTI : 296.47 (+0.99%)
IWM : 210.77 (+0.90%)
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

HUMA : 2.41 (+1.69%)
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

HUMA : 2.41 (+1.69%)
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

HUMA : 2.41 (+1.69%)
Humacyte, Inc. Announces Proposed Public Offering of Common Stock

HUMA : 2.41 (+1.69%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 2.55
2nd Resistance Point 2.50
1st Resistance Point 2.46
Last Price 2.41
1st Support Level 2.37
2nd Support Level 2.32
3rd Support Level 2.28

See More

52-Week High 9.79
Fibonacci 61.8% 6.49
Fibonacci 50% 5.47
Fibonacci 38.2% 4.45
Last Price 2.41
52-Week Low 1.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar